4//SEC Filing
DIACRIN INC /DE/ 4
Accession 0001104659-03-019529
CIK 0000887137operating
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 4:11 PM ET
Size
21.2 KB
Accession
0001104659-03-019529
Insider Transaction Report
Form 4
DIACRIN INC /DE/DCRN
FRASER THOMAS H
DirectorPresident & CEO
Transactions
- Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−65,000→ 0 totalExercise: $2.08Exp: 2012-01-14→ Common Stock (65,000 underlying) - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−20,000→ 0 totalExercise: $12.00Exp: 2007-03-17→ Common Stock (20,000 underlying) - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−50,000→ 0 totalExercise: $2.50Exp: 2003-12-02→ Common Stock (50,000 underlying) - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−25,000→ 0 totalExercise: $5.25Exp: 2008-12-21→ Common Stock (25,000 underlying) - Disposition to Issuer
Common Stock
2003-08-21−530,988 - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−30,000→ 0 totalExercise: $10.75Exp: 2007-12-17→ Common Stock (30,000 underlying)
Footnotes (9)
- [F1]Disposed of pursuant to a merger agreement between the issuer and GenVec, Inc. in exchange for 811,986 shares of GenVec common stock having an aggregate value of $1,875,688 on the effective date of the merger.
- [F2]These stock options, which provide for vesting in four equal annual installments beginning on December 17, 1998, were assumed by GenVec in connection with the merger and replaced with an option to purchase 45,876 shares of GenVec common stock at an exercise price of $7.03 per share.
- [F3]These stock options, which provide for vesting in four equal annual installments beginning on December 21, 1999, were assumed by GenVec in connection with the merger and replaced with an option to purchase 38,230 shares of GenVec common stock at an exercise price of $3.44 per share.
- [F4]These stock options, which provide for vesting in four equal annual installments beginning on December 30, 2000, were assumed by GenVec in connection with the merger and replaced with an option to purchase 38,230 shares of GenVec common stock at an exercise price of $4.09 per share.
- [F5]These stock options, which provide for vesting in four equal annual installments beginning on December 27, 2001, were assumed by GenVec in connection with the merger and replaced with an option to purchase 38,230 shares of GenVec common stock at an exercise price of $3.07 per share.
- [F6]These stock options, which provide for vesting in four equal annual installments beginning on January 14, 2003, were assumed by GenVec in connection with the merger and replaced with an option to purchase 99,398 shares of GenVec common stock at an exercise price of $1.36 per share.
- [F7]These stock options, which provide for vesting in four equal annual installments beginning on January 13, 2004, were assumed by GenVec in connection with the merger and replaced with an option to purchase 45,876 shares of GenVec common stock at an exercise price of $0.70 per share.
- [F8]This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 76,460 share of GenVec common stock at an exercise price of $1.64 per share.
- [F9]This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $7.85 per share.
Documents
Issuer
DIACRIN INC /DE/
CIK 0000887137
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000887137
Filing Metadata
- Form type
- 4
- Filed
- Aug 24, 8:00 PM ET
- Accepted
- Aug 25, 4:11 PM ET
- Size
- 21.2 KB